CONTENT VALIDATION AND DISCLOSURES

Research To Practice is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved by a peer review content validation process. The content of each activity is reviewed by both a member of the scientific staff and an external independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

In addition, the following faculty (and their spouses/partners) has reported real or apparent conflicts of interest that have been resolved through a peer review process:

Dr Sledge – Consultant: Genentech BioOncology. Dr Romond – No financial interests or affiliations to disclose. Dr Cuzick – Consultant: AstraZeneca Pharmaceuticals LP, Eli Lilly and Company, Pfizer Inc.

The scientific staff and consultants for Research To Practice are involved in the development and review of content for educational activities and report the following real or apparent conflicts of interest for themselves (or their spouses/partners) that have been resolved through a peer review process: Richard Kaderman, PhD, Neil Love, MD, Douglas Paley, Michelle Paley, MD, Margaret Peng, Lilliam Sklaver Poltorack, PharmD and Kathryn Ault Ziel, PhD – no real or apparent conflicts of interest to report; Sally Bogert, RNC, WHCNP – ownership interest in Amgen Inc; Terry Ann Glauser, MD, MPH – Speakers Bureau: AstraZeneca Pharmaceuticals LP, Biogen Idec, Genentech BioOncology, Sanofi-Aventis. Research To Practice receives education grants from Abraxis Oncology, Amgen sInc, AstraZeneca Pharmaceuticals LP, Biogen Idec, Genentech BioOncology, Genomic Health Inc, Roche Laboratories Inc and Sanofi-Aventis, which have no influence on the content development of our educational activities.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.